计算溶液所需的质量、体积或浓度。
| 活性类型 | 活性值-log(M) | 作用机制 | 期刊 | 参考文献(PubMed IDs) |
|---|
Moligand™ 级 提供 ≥98% 纯度,适用于对基线干扰要求严格的色谱和分析工作流程。
-20°C储存。超低温运输 。请查阅批次 COA 获取详细规格。
SDS、COA、产品数据表及规格说明书均可下载。可通过批号查询获取批次 COA。
在色谱分析、有机合成和交叉偶联反应领域已被 0 篇同行评审文献引用。
Information
Avapritinib (BLU-285) is a small molecule kinase inhibitor that potently inhibitsPDGFRα D842Vmutant activity in vitro (IC50 = 0.5 nM) and PDGFRα D842V autophosphorylation in the cellular setting (IC50 = 30 nM); also a potent inhibitor of the analogousKit (c-Kit)mutation, D816V in Kit (c-Kit) Exon 17 (IC50 = 0.5 nM).
Targets
PDGFRα (D842V) ; c-Kit (D816V) 0.5 nM; 0.5 nM
In vitro
BLU-285 is a selective oral inhibitor that targets KIT Exon 17 and PDGFRα D842 activation loop mutants. Cellular assays measuring inhibition of KIT mutant autophosphorylation confirm the activity of BLU-285 against the KIT D816 mutants D816V (HMC1.2 cells, IC50 = 3 nM) and D816Y (P815 cells, IC50 = 22 nM) as well as other KIT Exon 17 mutants such as N822K (Kasumi cells, IC50 = 40 nM) found in treatment-refractory GIST.
In vivo
BLU-285 is a well-tolerated, orally bioavailable agent that achieves dose dependent tumor growth inhibition in a D816Y-driven xenograft model. A PK-PD-efficacy relationship with BLU-285 has been established demonstrating that tumor regression results from >90% target suppression and is observed with 30 mg/kg once daily dosing. With potent activity against PDGFRα D842V and KIT Exon 17 mutants, BLU-285 targets previously unaddressed genomic drivers of disease and provides promise for the treatment of PDGFRα D842V-driven GIST(gastrointestinal stromal tumor) or SM(systemic mastocytosis), where more than 90% of patients carry the KIT D816V mutation. Besides single agent activity, the highly selective BLU-285 offers an opportunity for combination with other agents in GIST to cover the entirety of KIT primary and resistance mutants.
分类树(Taxonomy Tree)
| 界(kingdom) | 有机化合物 |
|---|---|
| 超类(Superclass) | 有机杂环化合物 |
| 类(Class) | 二嗪烷 |
| 亚类(Subclass) | 哌嗪类 |
| 中间层级节点(Intermediate Tree Nodes) | 暂无 |
| 直接上位类(Direct Parent) | N-芳基哌嗪 |
| 其他上位类(Alternative Parents) | 吡咯并[2,1-f][1,2,4]三嗪 二烷基芳胺 氟苯类 芳烷基胺 氨基嘧啶及其衍生物 取代吡咯 咪唑内酰胺类 芳基氟化物 1,2,4-三嗪 吡唑类 杂芳族化合物 氮杂环化合物 有机光子化合物 有机氟化物 单烷基胺 碳氢化合物衍生物 |
| 分子骨架(Molecular Framework) | 芳香族杂多环化合物 |
| 取代基(Substituents) | 1,2,4-三嗪 - 氨基酸 - 氨基吡啶 - 芳烷基胺 - 芳香族杂多环化合物 - 芳基氟化物 - 芳基卤化物 - 氮杂环 - 吡唑 - 苯基化合物 - 二烷基芳基胺 - 氟萘 - 卤苯 - 杂芳香族化合物 - 烃衍生物 - 咪唑内酰胺 - 单环苯基基团 - N-芳基哌嗪 - 有机硝基化合物 - 有机氟化物 - 有机卤化物 - 有机氮化合物 - 有机氮化合物 - 初级脂肪胺 - 初级胺 - 吡唑 - 嘧啶 - 吡咯 - Pyrrolo[2,1-f][1,2,4]triazine - 取代吡咯 - 三嗪 |
| 描述(Description) | 该化合物属于有机化合物中的n-芳基哌嗪类。这类化合物含有哌嗪环,其中氮环原子连接有芳基。 |
| 外部描述符(External Descriptors) | 暂无 |
| IC50 | PDGFRα (D842V), IC50: 0.5 nM |
|---|---|
| ALogP | 1.9 |
| 作用机制 | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | 参考文献 |
|---|
H302: 吞食有害
H315: 引起皮肤刺激
H319: 引起严重眼睛刺激
H335: 可能引起呼吸道刺激
P261: 避免吸入灰尘/烟雾/气体/雾/蒸汽/喷雾
P305+P351+P338: 如进入眼睛:用水小心冲洗几分钟。如戴隐形眼镜并可方便地取出,取出隐形眼镜。继续冲洗。